| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shaun Jordan, Karen Regardie, Janelle L Johnson, Ruoyan Chen, Junichi Kambayashi, Robert McQuade, Hisashi Kitagawa, Yoshihiro Tadori, Tetsuro Kikuch. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. Journal of psychopharmacology (Oxford, England). vol 21. issue 6. 2007-10-18. PMID:17092971. |
aripiprazole, (+)terguride, opc-4392 and (-)3-ppp have been classified as dopamine d(2) receptor partial agonists based largely on their activity in second messenger-based assays of dopamine d(2) receptor signalling. |
2007-10-18 |
2023-08-12 |
human |
| Shaun Jordan, Karen Regardie, Janelle L Johnson, Ruoyan Chen, Junichi Kambayashi, Robert McQuade, Hisashi Kitagawa, Yoshihiro Tadori, Tetsuro Kikuch. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. Journal of psychopharmacology (Oxford, England). vol 21. issue 6. 2007-10-18. PMID:17092971. |
we compared the intrinsic activity (e(max), expressed as a percentage of the maximal effect of dopamine) of aripiprazole, (+)terguride, opc-4392 and (-)3-ppp using second (calcium (ca(2+)) mobilization) and third (extracellular signal-regulated kinase 2 (erk2) phosphoprotein expression) messenger readouts of cloned human dopamine d(2long) (hd(2l)) receptor signalling in cho cells. |
2007-10-18 |
2023-08-12 |
human |
| Robert M Kessle. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism? The American journal of psychiatry. vol 164. issue 9. 2007-10-09. PMID:17728411. |
aripiprazole: what is the role of dopamine d(2) receptor partial agonism? |
2007-10-09 |
2023-08-12 |
Not clear |
| Joo-Cheol Shim, Jae-Goo K Shin, Deanna L Kelly, Do-Un Jung, Young-Soo Seo, Kwang-Hyeon Liu, Ji-Hong Shon, Robert R Conle. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. The American journal of psychiatry. vol 164. issue 9. 2007-10-09. PMID:17728426. |
adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. |
2007-10-09 |
2023-08-12 |
Not clear |
| Francesca Novi, Mark J Millan, Giovanni U Corsini, Roberto Maggi. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation. Journal of neurochemistry. vol 102. issue 4. 2007-10-04. PMID:17532788. |
partial agonist actions of aripiprazole and the candidate antipsychotics s33592, bifeprunox, n-desmethylclozapine and preclamol at dopamine d(2l) receptors are modified by co-transfection of d(3) receptors: potential role of heterodimer formation. |
2007-10-04 |
2023-08-12 |
Not clear |
| Antonio Pret. New developments in the pharmacotherapy of cocaine abuse. Addiction biology. vol 12. issue 2. 2007-08-17. PMID:17508985. |
on the basis of the known neurochemistry of cocaine, some target compounds have been studied: among others, bp-897, a d3 partial agonist; vanoxerine, a highly selective inhibitor of dopamine uptake; aripiprazole, a partial mixed-action agonist approved for the treatment of schizophrenia. |
2007-08-17 |
2023-08-12 |
Not clear |
| Andreas Fellgiebel, Matthias J Müller, Christoph Hiemke, Peter Bartenstein, Matthias Schreckenberge. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 8. issue 2. 2007-08-01. PMID:17455105. |
we examined the clinical effects of aripiprazole, a new antipsychotic with partial agonistic properties at serotonin 5-ht(1a) and dopamine d(2) receptors, in parallel with cortical glucose metabolism changes. |
2007-08-01 |
2023-08-12 |
Not clear |
| Lauren D LaPort. Relief from migraine headache with aripiprazole treatment. Headache. vol 47. issue 6. 2007-08-01. PMID:17578547. |
this report documents 3 cases of female migraineurs who received the dopamine modulator aripiprazole for treatment of co-occurring psychiatric disorders and experienced a decrease in migraine frequency and severity. |
2007-08-01 |
2023-08-12 |
Not clear |
| Yu-Chih Shen, Shaw-Ji Chen, Chaucer C H Lin, Chia-Hsiang Che. Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome? International clinical psychopharmacology. vol 22. issue 4. 2007-07-24. PMID:17519650. |
on the basis of the glutamate and dopamine neuron dysregulation hypothesis in schizophrenia, we propose new strategies for the treatment of schizophrenic patients using a glutamate system stabilizer lamotrigine as an adjunctive treatment for the poor responders of a dopamine system stabilizer, aripiprazole. |
2007-07-24 |
2023-08-12 |
Not clear |
| Martyn Wood, Charlie Reavil. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert opinion on investigational drugs. vol 16. issue 6. 2007-07-20. PMID:17501690. |
aripiprazole acts as a selective dopamine d2 receptor partial agonist. |
2007-07-20 |
2023-08-12 |
Not clear |
| Martyn Wood, Charlie Reavil. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert opinion on investigational drugs. vol 16. issue 6. 2007-07-20. PMID:17501690. |
it has been claimed that partial agonism of the dopamine d(2) and 5-ht(1a) receptors and antagonism of the 5-ht(2) receptor contribute to the clinical profile of aripiprazole, a so-called dopamine- and 5-ht stabiliser. |
2007-07-20 |
2023-08-12 |
Not clear |
| Martyn Wood, Charlie Reavil. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert opinion on investigational drugs. vol 16. issue 6. 2007-07-20. PMID:17501690. |
this report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine d(2) receptor and does not affect 5-ht receptors at therapeutic doses. |
2007-07-20 |
2023-08-12 |
Not clear |
| Arlene D Stark, Shaun Jordan, Kelly A Allers, Robert L Bertekap, Ruoyan Chen, Tanaz Mistry Kannan, Thaddeus F Molski, Frank D Yocca, Trevor Sharp, Tetsuro Kikuchi, Kevin D Burri. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology. vol 190. issue 3. 2007-06-18. PMID:17242925. |
aripiprazole interacts with a range of receptors, including serotonin [5-hydroxytryptamine (5-ht)] and dopamine receptors. |
2007-06-18 |
2023-08-12 |
Not clear |
| Mark J Millan, Loretta Iob, Jean-Louis Péglion, Anne Dekeyn. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors. Psychopharmacology. vol 191. issue 3. 2007-06-12. PMID:17047933. |
discriminative stimulus properties of s32504, a novel d3/d2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, n-desmethylclozapine, and by selective antagonists at dopamine d2 but not d3 receptors. |
2007-06-12 |
2023-08-12 |
rat |
| Takashi Hamamura, Toshiki Harad. Unique pharmacological profile of aripiprazole as the phasic component buster. Psychopharmacology. vol 191. issue 3. 2007-06-12. PMID:17205315. |
aripiprazole is a recently introduced antipsychotic with a unique pharmacological profile, a dopamine partial agonist. |
2007-06-12 |
2023-08-12 |
Not clear |
| A Bortolozzi, L Díaz-Mataix, M Toth, P Celada, F Artiga. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology. vol 191. issue 3. 2007-06-12. PMID:17265076. |
aripiprazole is an atypical antipsychotic drug with high in vitro affinity for 5-ht(1a), 5-ht(2a) and dopamine (da) d2 receptors. |
2007-06-12 |
2023-08-12 |
Not clear |
| Pietro Gareri, Pasquale De Fazio, Salvatore De Fazio, Norma Marigliano, Guido Ferreri Ibbadu, Giovambattista De Sarr. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs & aging. vol 23. issue 12. 2007-05-01. PMID:17154659. |
new antipsychotics, such as amisulpride, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, zotepine and aripiprazole, may interact with both dopamine and serotonin receptors. |
2007-05-01 |
2023-08-12 |
Not clear |
| Shaun Jordan, Janelle L Johnson, Karen Regardie, Ruoyan Chen, Vuk Koprivica, Yoshihiro Tadori, Junichi Kambayashi, Hisashi Kitagawa, Tetsuro Kikuch. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 2. 2007-04-24. PMID:17070976. |
here, we used dopamine d(2) receptor signaling assays to compare the in vitro functional characteristics of the antipsychotic aripiprazole with other dopamine d(2) receptor partial agonists (7-{3-[4-(2,3-dimethylphenyl)-piperazinyl]propoxy}-2(1h)-quinolinone [opc-4392], (-)-3-(3-hydroxy-phenyl)-n-n-propylpiperidine [(-)3-ppp] and (+)terguride) and dopamine d(2) receptor antagonists. |
2007-04-24 |
2023-08-12 |
human |
| Shaun Jordan, Janelle L Johnson, Karen Regardie, Ruoyan Chen, Vuk Koprivica, Yoshihiro Tadori, Junichi Kambayashi, Hisashi Kitagawa, Tetsuro Kikuch. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 2. 2007-04-24. PMID:17070976. |
aripiprazole and opc-4392 were inactive in a guanosine-5'-o-(3-[(35)s]thio)-triphosphate ([(35)s]gtpgammas) binding assay using chinese hamster ovary (cho) cell membranes expressing cloned human dopamine d(2long) (hd(2l)) receptors, whereas (-)3-ppp and (+)terguride displayed low intrinsic activity. |
2007-04-24 |
2023-08-12 |
human |
| Shaun Jordan, Janelle L Johnson, Karen Regardie, Ruoyan Chen, Vuk Koprivica, Yoshihiro Tadori, Junichi Kambayashi, Hisashi Kitagawa, Tetsuro Kikuch. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 2. 2007-04-24. PMID:17070976. |
however, at a more downstream level of cho-hd(2l) cell signalling, these drugs all behaved as dopamine hd(2l) receptor partial agonists, with aripiprazole displaying an intrinsic activity 2 to 3-fold lower (inhibition of forskolin-induced adenosine 3',5'-cyclic monophosphate accumulation) and almost half as high (enhancement of adenosine triphosphate-stimulated [(3)h]arachidonic acid release) as opc-4392, (-)3-ppp and (+)terguride. |
2007-04-24 |
2023-08-12 |
human |